Supernus Pharmaceuticals completes its strategic merger with Indivior, creating a new, diversified biopharmaceutical leader dedicated to advancing treatments for central nervous system conditions.
Supernus has successfully finalized its merger with Indivior to form a new, unified entity under the Supernus, Inc. name. This strategic combination aims to establish a market-leading position in the CNS biopharmaceutical sector by integrating the portfolios and resources of both companies.
The combined entity is officially operating as Supernus, Inc.
The company is dedicated to treating patients living with central nervous system (CNS) diseases.
Indivior has completed its merger with Supernus, effectively transitioning its operations into the newly formed Supernus, Inc. entity. This consolidation marks a significant shift in corporate structure for Indivior shareholders as the company integrates into a broader CNS-focused biopharmaceutical platform.
Indivior has merged with Supernus Pharmaceuticals to form a new, combined company called Supernus, Inc.
No, Indivior has been combined with Supernus to create a leading diversified biopharmaceutical company.
Supernus Pharmaceuticals has finalized its merger with Indivior, establishing a diversified biopharmaceutical entity focused on central nervous system treatments. The combined company aims to leverage expanded resources to address complex CNS diseases, marking a significant consolidation in the sector.
The combined company is dedicated to developing and providing treatments for patients living with central nervous system (CNS) diseases.